UK Revokes Marketing Authorization for IXCHIQ®; Valneva Continues Brazil Trials
1 report, 1 independent
Updated Oct 1
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The Medicines and Healthcare products Regulatory Agency revoked the UK marketing authorization for IXCHIQ® following a benefit-risk assessment of the vaccine for travelers. This decision was based on a review of previous safety data and did not identify any new safety signals. The product licenses for IXCHIQ® remain valid in the EU, Canada, and Brazil.
From manilatimes.net
Why it matters
Valneva expects minimal impact on its overall sales revenue due to the revocation, as the product was not actively distributed in the UK. The company continues its pilot vaccination strategy in Brazil, where over 61,000 people have been vaccinated without new safety concerns.
From manilatimes.net
Who's involved
- European Medicines AgencyThe European Medicines Agency conducted similar safety reviews regarding the vaccine.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- European Commission must manage EU market status amid vaccine reviewThe European Commission must manage EU market status despite UK regulatory changesLikely
- Chikungunya virus spread may increase pressure on health servicesIncreased global focus on Chikungunya virus may heighten advisory needs for health servicesPossible
Keep exploring
The entities involved
-
AEDES
business
-
European Medicines Agency
highest regulatory authority on medicines in the European Union